Xanthine oxido-reductase, free radicals and cardiovascular disease. A critical review

Pathology and Oncology Research

Volumn 20, Issue 1, 2014, Pages 1-10

  Robert, A M ^a   Robert, L ^a,b  

^a HÔTEL DIEU   (France)

^b NONE   (France)

Author keywords

Allopurinol; Cardiovascular disease; Free radicals; ROS; Xanthine oxidase

Indexed keywords

ALLOPURINOL; FREE RADICAL; HYPOXANTHINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUNGSTEN; URIC ACID; XANTHINE OXIDASE;

BACTERICIDAL ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE MUTATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INTESTINE EPITHELIUM CELL; INTRACELLULAR SIGNALING; LACTATION; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; VASODILATATION; XOR GENE;

ANIMALS; CARDIOVASCULAR DISEASES; FREE RADICALS; HUMANS; REACTIVE OXYGEN SPECIES; XANTHINE DEHYDROGENASE;

EID: 84896054244     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9698-x     Document Type: Review

References (70)

1. Robert L, Labat-Robert J, Robert AM (2010) Vieillissement cellulaire, télomères et maladies liées à l'âge. Médecine & Longévité 2:151-161. doi:10.1016/j.mlong. 2010.07.005
2. Harman D (1955) Aging - a theory based on free radical and information theory U.C.R.L. Publ., 3078, Univ. of Calif.
3. Comfort A (1979) The biology of senescence, 3rd edn. Churchill Livingstone, Edinburgh & London, 1979
4. Emerit I, Eds BC (1992) Free radicals and aging. Birkhäuser Verlag, Basel, 1992
5. Edeas M (2009) Anti-oxydants, controverses et perspectives: comment expliquer l'échec des etudes cliniques utilisant des antioxydants. J Soc Biol 203:271-280
6. Blokhina O, Virolainen E, Fagerstedt KV (2003) Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot 91:179-194
7. Martin HM, Hancock JT, Salisbury V, Harrison R (2004) Mini-review. Role of xanthine oxydoreductase as an antimicrobial agent. Infect Immun 72:4933-4939 (Pubitemid 39223375)
8. Miller SL, Urey HC (1959) Organic compound synthesis on the primitive earth. Science 130:245-251
9. Garattini E, Mendel R, Romao MJ, Wright R, Terao M (2003) Review article. Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 372:15-32
10. Drury AN, Szent-Györgyi A (1929) The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68:213-237
11. Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic signaling during inflammation. New Engl J Med 367:2322-2333
12. Patton S, Keenan TW (1975) The milk fat globule membrane. Biochim Biophys Acta 415:273-309
13. Dowben RM, Brunner JR, Philpott DE (1967) Studies on milk fat globule membranes. Biochim Biophys Acta 135:1-10
14. Polonovski M, Robert M, Robert L (1950) Cinétique de la révélation de la xanthinedéhydrase du lait de vache. Bull Soc Chim Biol 32:862-867
15. Polonovski M, Baudu L, Robert M, Robert L (1950) Données nouvelles sur la révélation de la xanthine-déhydrase du lait par les agents chimiques. Bull Soc Chim Biol 32:855-861
16. Polonovski M, Robert L, Robert M (1950) Une nouvelle méthode d'extraction et de purification de la xanthine déhydrase du lait. Bull Soc Chim Biol 32:868-871
17. Robert L, Basset J (1953) Action des hautes pressions sur la xanthinedéhydrase du lait. Bull Soc Chim Biol 35:1375-1380
18. Robert L, Nolla N (1953) Action des ultrasons sur la xanthinedé hydrase du lait. Bull Soc Chim Biol 35:1363-1373
19. Robert L, Polonovski M (1955) Activation and inactivation of milk xanthineoxydase by physicochemical means. In: Discussions of the Faraday Society, No 20, The Physical Chemistry of Enzymes The Aberdeen University Press Ltd; 6 Upper Kirkgate, Aberdeen, pp 54- 65
20. Avis PG, Berger F, Bray RC, Shooter KV (1954) A crystalline material with xanthine oxidase activity. Nature 173:1230-1233
21. Avis PG, Bergel F, Bray RC (1955) Cellular constituents. The chemistry of xanthine oxidase. Pat I. The preparation of a crystalline xanthine oxidase from cow's milk. J Chem Soc April 1100-1105
22. Avis PG, Bergel F, Bray RC, James DWF, Shooter KV (1956) Cellular constituents. The chemistry of xanthine oxidase. Part II. The homogeneity of crystalline metalloflavoprotein fractions. J Chem Soc 252:1212-1219
23. Avis PG, Bergel F, Bray RC (1956) Cellular constituents. The chemistry of xanthine oxidase. Part III. Estimations of the co-factors and the catalytic activities of enzyme fractions from cow's milk. J Chem Soc 253:1219-1226
24. Bergel F, Bray RC (1959) The chemistry of xanthine oxidase. 4. The problems of enzyme inactivation and stabilisation. Biochem J 73: 182-192
25. Bray RC, Chisholm AJ, Hart LI, Meriwether LS, Watts DC (1966) Studies on the composition andmechanism of action of milk xanthine oxidase. In: Slater EC (ed) Flavins and flavoproteins. Elsevier Publishing Company, Amsterdam, pp 117-132
26. Haddow A, de Lamirande G, Bergel F, Bray RC, Gilbert DA (1958) Anti-tumour and biochemical effects of purified bovine xanthine oxidase in C3H and C mice. Nature 182:1144-1146
27. Mackler B, Mahler HR, Green DE (1954) Studies on metalloflavoproteins. I. Xanthine oxydase. A molybdoflavoprotein. J Biol Chem 210:149-164
28. Berry CE, Hare JM (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555:589-606 (Pubitemid 38404582)
29. Granger DN, Rutili G, McCord J (1981) Superoxide radicals in feline intestinal ischemia. Gastroenterology 81:22-29 (Pubitemid 11078477)
30. Carden DI, Granger DN (2000) Pathology of ischemia-reperfusion injury. J Pathol 190:255-266
31. Harrison R (2002) Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33:774-797
32. Granger DN, Rutili G, McCord JM (1981) Superoxide radicals in feline intestinal ischemia. Gastroenterology 81:22-29 (Pubitemid 11078477)
33. Abadeh S, Killacky J, Benboubetra M, Harrison R (1992) Purification and partial characterization of xanthine oxidase from human milk. Biochim Biophys Acta 1117:25-32
34. Vorbach C, Scriven A, Capecchi MR (2002) The housekeeper gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes Dev 16:3223-3235 (Pubitemid 36025975)
35. Simmonds HA (1994) Purine and pyrimidine disorders. In: Holton JS (ed) The Inherited metabolic diseases, 2nd edn. Churchill Livingstone, New York, pp 297-307
36. Delbarre F, Cartier P, Auscher C, De Géry A, Hamet M (1970) Gouttes enzymopathiques. Dyspurinies par déficit en Hypoxanthine-Guanine- Phosphoribosyl-Transférase. Fréquence et caractères cliniques de l'anenzymose. Presse Med 78:729-734
37. Ea H-K, Bardin T, Jinnah HA, Aral B, Lioté F, Ceballos - Picot I (2009) Severe Gouty Arthritis and mild neurologic symptoms due to F199C, a newly identified variant of the hypoxanthine guanine phosphoribosyltransferase. Arthritis Rheum 60:2201-2220
38. Lewers JC, Ceballos-Picot I, Shirley TL, Mockel L, Egami K, Jinnah HA (2008) Consequences of impaired purine recycling in dopaminergic neurons. Neuroscience 152:761-772
39. Bollée G, Dollinger C, Boutaud L, Guillemot D, Bensman A, Harambat J, Deteix P, Daudon M, Knebelmann B, Ceballos-Picot I (2010) Phenotype and genotype characterization of adenine phosphoribosyltransfetrase deficiency. J Am Soc Nephrol 4:679-688
40. Jinnah HA, Ceballos-Picot I, Torres RJ, Visser JE, Schretlen DJ, Verdu A, Larovere LE, Chen S-J, Cossu A et al (2010) Attenuated variants of Lesch-Nyhan disease. Brain 133:671-689
41. Li H, Samouilov A, Liu X, Zweier JL (2003) Characterization of the magnitude and kinetics of xanthine oxidase - catalysed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry 42:1150-1159 (Pubitemid 36159550)
42. Kayyali US, Donaldson C, Huang H, Abdelnour R, Hassoun PM (2001) Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia. J Biol Chem 276:14359-14365
43. Adachi T, Fukushima T, Usami Y, Hirano K (1993) Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial cell surface. Biochem J 289:523-527 (Pubitemid 23042063)
44. Brown JM, Terrada LS, Grosso MA, Whitmann GJ, Velasco SE, Patt A, Harken AH, Repine JE (1988) Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated, perfused rat hearts. J Clin Invest 81:1297-1301
45. Wang W, Sawicki G, Schulz R (2002) Peroxinitrite - induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 53:165-174 (Pubitemid 34020777)
46. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JRB, Sawicki G, Schulz R (2002) Intracellular action of matrix metalloproteinase - 2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106:1543-1549
47. Campbell DL, Stamler JS, Strauss HC (1996) Redox modulation of L-type calcium channels in ferret ventricular myocytes dual mechanism regulation by nitric oxide and S-nitrosothiols. J General Physiol 108:277-293 (Pubitemid 26332539)
48. Ohara Y, Peterson TE, Harrison DG (1993) Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546-2551 (Pubitemid 23182507)
49. Burns CM, Wortmann RL (2012) Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis 3(6):271-286
50. Truglio JJ, Theis K, Leimkühler S, Rappa R, Rajagopalan KV, Kisker C (2002) Crystal structures of the active and alloxanthine-inhibited forms of xanthine dehydrogenase from Rhodobacter capsulatus. Structure 10:115-125 (Pubitemid 34112616)
51. Sanders S, Eisenthal RS, Harrison R (1997) NADH oxidase activity of human xanthine oxidoreductase -generation of superoxide anion. Eur J Biochem 245:541-548 (Pubitemid 27223884)
52. Brown JM, Terada LS, Grosso MA, Whitmann GJ, Velasco SE, Patt A, Harken AH, Repine JE (1988) Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated perfused rat hearts. J Clin Invest 81:1297-1301
53. Grisham MB, Hernandez LA, Granger DN (1986) Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol 251:G567-G574
54. Gimpel JA, Lahpor JR, van der Molen A, Damen J, Hitchcock JF (1995) Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study. Free Radic Biol Med 19:251-255
55. Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, Iwasa A, Fujita N, Kudo S, Ohkubo T OK (2003) Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol 41:699-705 (Pubitemid 36523171)
56. Butler R, Morris AD, Belch JJF, Hill A, Struthers AD (2000) Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35:746-751 (Pubitemid 30165320)
57. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Iwasaki T (2003) Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 88:10045-10048
58. Kögler H, Fraser H, McCune S, Altschuld R, Marban E (2003) Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res 59:582-592 (Pubitemid 38368674)
59. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, Hare JM (2001) Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104:2407-2411 (Pubitemid 33108372)
60. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811-18 21
61. Galiardi AC, Miname MH, Santos RD (2009) Uric acid: a marker of increased cardiovascular risk. Atherosclerosis 202:11-17
62. Krishnan E, Baker JF, Furst DE, Schumacher HR (2006) Gout and the risk of acute myocardial infarction. Arthritis Rheum 54:2688-2696 (Pubitemid 44208638)
63. Krishnan E, Pandya BJ, Lingala B, Hariri A, Dabbous O (2012) Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther 14:R10
64. Baker JF, Schumacher HR, Krishnan E (2007) Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 58:450-457 (Pubitemid 47301052)
65. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller RH (2008) Long-term cardiovascular mortality among middle - aged men with gout. Arch Intern Med 168:1104-1110 (Pubitemid 351749228)
66. Choi HK, Curhan G (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116:894-900 (Pubitemid 47300913)
67. Hanassoulis G, Brophy JM, Richard H, Pilote L (2010) Gout, allopurinol use and heart failure outcomes. Arch Intern Med 170:1358-1364
68. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD (2010) Effect of high - dose allopurinol on exercise in patients with chronic stable angina: a randomized, placebo controlled crossover trial. Lancet 375:2161-2167
69. Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924-932
70. Kelkar A, Kuo A, Frishman WH (2011) Allopurinol as a cardiovascular drug. Cardiol Rev 19:265-271